Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201312115 Principal Investigator: Cashen, Amanda
Title: A phase II study of melphalan HCl for injection (propylene glycol-free), combined with carmustine, etoposide, and cytarabine (BEAM regimen) for myeloablative conditioning in lymphoma patients undergoing autologous stem cell transplantation
Phase: II Disease Site: Lymphoid Leukemia
Participating Site(s):
 
Main Campus
Map and Directions
South County
Map and Directions
West County
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this research study is to determine the safety, side effects, and effectiveness of a new formulation of melphalan when it is administered as part of the BEAM regimen, which is given prior to stem cell transplant. BEAM is a 4-drug chemotherapy combination using the following drugs: carmustine (also called BCNU), etoposide, cytarabine (also called Ara-C), and melphalan.
 
More Information:
ClinicalTrials.Gov Link
Internal Protocol Documents (requires Siteman administrative database password)